Low-dose nivolumab in advanced hepatocellular carcinoma

The approved dose of nivolumab is 3mg/kg or a fat dose of 240mg for indications. There is no doseresponse relationship for nivolumab; therefore, a low-dose regimen may be an option to reduce financial toxicity. This study was designed to investigate the efcacy and safety of low-dose nivolumab in the management of hepatocellular carcinoma (HCC).